LANSING, Mich., Dec. 21, 2023 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Thursday, January 11, 2024.
John Adent, Neogen's President and Chief Executive Officer, will present at 9:00 a.m. Pacific Time.
To access the webcast and presentation materials, please visit the Events & Presentations section of the Neogen Investor Relations website at neogen.com/investor-relations/events-presentations and click on the event webcast link.
About Neogen
Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Contact
Bill Waelke — VP, IR & Treasury
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$12.04 |
| Daily Change: | 0.02 0.17 |
| Daily Volume: | 3,366,036 |
| Market Cap: | US$2.610B |
December 17, 2024 October 10, 2024 July 30, 2024 June 27, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
